{"transactions":[{"id":4614045,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":47329,"kind":"person","name":"Nicholson Nur","position":1,"cik":"0001827317","reported_name":"Nicholson Nur","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technology Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-09-09T23:29:45.000Z","date":"2026-09-07","kind":"grant","planned":false,"acquired":true,"shares":220000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest and become exercisable as to 25% of the underlying shares on August 31, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service through each such vesting date."}],"balance_after":220000,"derivative":{"exercise_price":16.23,"expiration_date":"2036-09-07","underlying":"Common Stock","underlying_shares":220000},"source":{"system":"sec-edgar","filing":"0001193125-26-386782","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2096997/000119312526386782/ownership.xml","form_type":"4"}},{"id":712330,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":31380,"kind":"person","name":"Tregoning Kathleen","position":1,"cik":"0001830764","reported_name":"Tregoning Kathleen","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2026-07-08T20:20:04.000Z","date":"2026-07-06","kind":"grant","planned":false,"acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest and become exercisable as to 25% of the underlying shares on June 29, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service through each such vesting date."}],"balance_after":175000,"derivative":{"exercise_price":23.3,"expiration_date":"2036-07-06","underlying":"Common Stock","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0001193125-26-298558","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1830764/000119312526298558/ownership.xml","form_type":"4"}},{"id":741293,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Stock Option (right to buy)","published_at":"2026-06-11T20:05:10.000Z","date":"2026-06-09","kind":"exercise","planned":false,"acquired":false,"shares":38094,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vested and became exercisable as to 33% of the total shares on September 9, 2025 and thereafter in 24 substantially equal monthly installments, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":817826,"derivative":{"exercise_price":5.25,"expiration_date":"2034-09-19","underlying":"Common Stock","underlying_shares":38094},"source":{"system":"sec-edgar","filing":"0001193125-26-267493","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1354434/000119312526267493/ownership.xml","form_type":"4"}},{"id":741292,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-06-11T20:05:10.000Z","date":"2026-06-09","kind":"exercise","planned":false,"acquired":true,"shares":38094,"price":5.25,"value":199993.5,"ownership":{"direct":true},"balance_after":38094,"source":{"system":"sec-edgar","filing":"0001193125-26-267493","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1354434/000119312526267493/ownership.xml","form_type":"4"}},{"id":802767,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-04-22T20:15:07.000Z","date":"2026-04-20","kind":"exercise","planned":false,"acquired":false,"shares":2026820,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-1 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-1 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-1 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-1 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held by certain affiliated funds managed by RTW Investments, LP (\"RTW\"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of RTW. The Reporting Persons disclaim beneficial ownership of the reported securities for purposes of Section 16 under the Securities Exchange Act of 1934, as amended, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2026820},"source":{"system":"sec-edgar","filing":"0001231919-26-000390","document":"form4-04222026_040401.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000123191926000390/form4-04222026_040401.xml","form_type":"4"}},{"id":802766,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2026-04-22T20:15:07.000Z","date":"2026-04-20","kind":"exercise","planned":false,"acquired":false,"shares":8250000,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-1 basis and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-1 basis and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-1 basis and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-1 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held by certain affiliated funds managed by RTW Investments, LP (\"RTW\"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of RTW. The Reporting Persons disclaim beneficial ownership of the reported securities for purposes of Section 16 under the Securities Exchange Act of 1934, as amended, except to the extent of their pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":8250000},"source":{"system":"sec-edgar","filing":"0001231919-26-000390","document":"form4-04222026_040401.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000123191926000390/form4-04222026_040401.xml","form_type":"4"}},{"id":802765,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-22T20:15:07.000Z","date":"2026-04-20","kind":"purchase","planned":false,"acquired":true,"shares":500000,"price":16,"value":8000000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held by certain affiliated funds managed by RTW Investments, LP (\"RTW\"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of RTW. The Reporting Persons disclaim beneficial ownership of the reported securities for purposes of Section 16 under the Securities Exchange Act of 1934, as amended, except to the extent of their pecuniary interest therein."}],"balance_after":10776820,"source":{"system":"sec-edgar","filing":"0001231919-26-000390","document":"form4-04222026_040401.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000123191926000390/form4-04222026_040401.xml","form_type":"4"}},{"id":802764,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":28978,"kind":"organization","name":"RTW INVESTMENTS, LP","position":1,"cik":"0001493215","reported_name":"RTW INVESTMENTS, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":27749,"kind":"person","name":"WONG RODERICK","position":2,"cik":"0001493280","reported_name":"WONG RODERICK","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-22T20:15:07.000Z","date":"2026-04-20","kind":"exercise","planned":false,"acquired":true,"shares":10276820,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering for no additional consideration on a 1-for-1 basis and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held by certain affiliated funds managed by RTW Investments, LP (\"RTW\"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of RTW. The Reporting Persons disclaim beneficial ownership of the reported securities for purposes of Section 16 under the Securities Exchange Act of 1934, as amended, except to the extent of their pecuniary interest therein."}],"balance_after":10276820,"source":{"system":"sec-edgar","filing":"0001231919-26-000390","document":"form4-04222026_040401.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1493215/000123191926000390/form4-04222026_040401.xml","form_type":"4"}},{"id":802313,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":24906,"kind":"organization","name":"Jiangsu Hengrui Pharmaceuticals Co., Ltd.","position":1,"cik":"0002080343","reported_name":"Jiangsu Hengrui Pharmaceuticals Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 convertible non-voting preferred stock","published_at":"2026-04-22T10:03:23.000Z","date":"2026-04-20","kind":"exercise","planned":false,"acquired":false,"shares":708814,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series A-2 convertible preferred stock and Series A-2 convertible non-voting preferred stock (collectively, the \"Preferred Stock\") of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series A-2 convertible preferred stock and Series A-2 convertible non-voting preferred stock (collectively, the \"Preferred Stock\") of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series A-2 convertible preferred stock and Series A-2 convertible non-voting preferred stock (collectively, the \"Preferred Stock\") of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2034133},"source":{"system":"sec-edgar","filing":"0001104659-26-046276","document":"tm2612225-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/2096997/000110465926046276/tm2612225-1_4seq1.xml","form_type":"4"}},{"id":802312,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":24906,"kind":"organization","name":"Jiangsu Hengrui Pharmaceuticals Co., Ltd.","position":1,"cik":"0002080343","reported_name":"Jiangsu Hengrui Pharmaceuticals Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 convertible preferred stock","published_at":"2026-04-22T10:03:23.000Z","date":"2026-04-20","kind":"exercise","planned":false,"acquired":false,"shares":4968789,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series A-2 convertible preferred stock and Series A-2 convertible non-voting preferred stock (collectively, the \"Preferred Stock\") of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series A-2 convertible preferred stock and Series A-2 convertible non-voting preferred stock (collectively, the \"Preferred Stock\") of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series A-2 convertible preferred stock and Series A-2 convertible non-voting preferred stock (collectively, the \"Preferred Stock\") of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":9477719},"source":{"system":"sec-edgar","filing":"0001104659-26-046276","document":"tm2612225-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/2096997/000110465926046276/tm2612225-1_4seq1.xml","form_type":"4"}},{"id":802311,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":24906,"kind":"organization","name":"Jiangsu Hengrui Pharmaceuticals Co., Ltd.","position":1,"cik":"0002080343","reported_name":"Jiangsu Hengrui Pharmaceuticals Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-22T10:03:23.000Z","date":"2026-04-20","kind":"exercise","planned":false,"acquired":true,"shares":2034133,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series A-2 convertible preferred stock and Series A-2 convertible non-voting preferred stock (collectively, the \"Preferred Stock\") of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock."}],"balance_after":2034133,"source":{"system":"sec-edgar","filing":"0001104659-26-046276","document":"tm2612225-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2096997/000110465926046276/tm2612225-1_4seq1.xml","form_type":"4"}},{"id":802310,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":24906,"kind":"organization","name":"Jiangsu Hengrui Pharmaceuticals Co., Ltd.","position":1,"cik":"0002080343","reported_name":"Jiangsu Hengrui Pharmaceuticals Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-22T10:03:23.000Z","date":"2026-04-20","kind":"exercise","planned":false,"acquired":true,"shares":9477719,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series A-2 convertible preferred stock and Series A-2 convertible non-voting preferred stock (collectively, the \"Preferred Stock\") of the Issuer are convertible into shares of Common Stock of the Issuer at the holder's election and have no expiration date. All shares of the Preferred Stock automatically converted into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering of its Common Stock."}],"balance_after":9477719,"source":{"system":"sec-edgar","filing":"0001104659-26-046276","document":"tm2612225-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2096997/000110465926046276/tm2612225-1_4seq1.xml","form_type":"4"}},{"id":804924,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":52008,"kind":"organization","name":"Bain Capital Investors LLC","position":1,"cik":"0001040508","reported_name":"BAIN CAPITAL INVESTORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":52009,"kind":"organization","name":"Bain Capital XIV General Partner, LLC","position":2,"cik":"0002016388","reported_name":"Bain Capital XIV General Partner, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":52010,"kind":"organization","name":"Bain Capital Fund XIV, L.P.","position":3,"cik":"0002016381","reported_name":"Bain Capital Fund XIV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":52011,"kind":"organization","name":"BCPE Perseus Investor GP, LLC","position":4,"cik":"0002100155","reported_name":"BCPE Perseus Investor GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":52012,"kind":"organization","name":"BCPE Perseus Investor, LP","position":5,"cik":"0002100174","reported_name":"BCPE Perseus Investor, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-04-20T22:10:33.000Z","date":"2026-04-20","kind":"exercise","planned":false,"acquired":false,"shares":17857143,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents securities held directly by BCPE Perseus Investor, LP (\"BCPE Perseus\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bain Capital Investors, LLC (\"BCI\") is the manager of Bain Capital XIV General Partner, LLC (\"BCPE Fund XIV GP\"), which is the general partner of Bain Capital Fund XIV, L.P. (\"BCPE Fund XIV\"), which is the managing member of BCPE Perseus Investor GP, LLC (\"BCPE Perseus GP\"), which is the general partner of BCPE Perseus. As a result, each of BCI, BCPE Fund XIV GP, BCPE Fund XIV and BCPE Perseus GP may be deemed to share voting and dispositive power with respect to the securities held by BCPE Perseus. BCI, BCPE Fund XIV GP, BCPE Fund XIV and BCPE Perseus GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":17857143},"source":{"system":"sec-edgar","filing":"0001193125-26-164417","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1040508/000119312526164417/ownership.xml","form_type":"4"}},{"id":804923,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":52008,"kind":"organization","name":"Bain Capital Investors LLC","position":1,"cik":"0001040508","reported_name":"BAIN CAPITAL INVESTORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":52009,"kind":"organization","name":"Bain Capital XIV General Partner, LLC","position":2,"cik":"0002016388","reported_name":"Bain Capital XIV General Partner, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":52010,"kind":"organization","name":"Bain Capital Fund XIV, L.P.","position":3,"cik":"0002016381","reported_name":"Bain Capital Fund XIV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":52011,"kind":"organization","name":"BCPE Perseus Investor GP, LLC","position":4,"cik":"0002100155","reported_name":"BCPE Perseus Investor GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":52012,"kind":"organization","name":"BCPE Perseus Investor, LP","position":5,"cik":"0002100174","reported_name":"BCPE Perseus Investor, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-20T22:10:33.000Z","date":"2026-04-20","kind":"purchase","planned":false,"acquired":true,"shares":8398438,"price":16,"value":134375008.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents securities held directly by BCPE Perseus Investor, LP (\"BCPE Perseus\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bain Capital Investors, LLC (\"BCI\") is the manager of Bain Capital XIV General Partner, LLC (\"BCPE Fund XIV GP\"), which is the general partner of Bain Capital Fund XIV, L.P. (\"BCPE Fund XIV\"), which is the managing member of BCPE Perseus Investor GP, LLC (\"BCPE Perseus GP\"), which is the general partner of BCPE Perseus. As a result, each of BCI, BCPE Fund XIV GP, BCPE Fund XIV and BCPE Perseus GP may be deemed to share voting and dispositive power with respect to the securities held by BCPE Perseus. BCI, BCPE Fund XIV GP, BCPE Fund XIV and BCPE Perseus GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."}],"balance_after":26255581,"source":{"system":"sec-edgar","filing":"0001193125-26-164417","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1040508/000119312526164417/ownership.xml","form_type":"4"}},{"id":804922,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":52008,"kind":"organization","name":"Bain Capital Investors LLC","position":1,"cik":"0001040508","reported_name":"BAIN CAPITAL INVESTORS LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":52009,"kind":"organization","name":"Bain Capital XIV General Partner, LLC","position":2,"cik":"0002016388","reported_name":"Bain Capital XIV General Partner, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":52010,"kind":"organization","name":"Bain Capital Fund XIV, L.P.","position":3,"cik":"0002016381","reported_name":"Bain Capital Fund XIV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":52011,"kind":"organization","name":"BCPE Perseus Investor GP, LLC","position":4,"cik":"0002100155","reported_name":"BCPE Perseus Investor GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":52012,"kind":"organization","name":"BCPE Perseus Investor, LP","position":5,"cik":"0002100174","reported_name":"BCPE Perseus Investor, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-20T22:10:33.000Z","date":"2026-04-20","kind":"exercise","planned":false,"acquired":true,"shares":17857143,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents securities held directly by BCPE Perseus Investor, LP (\"BCPE Perseus\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Bain Capital Investors, LLC (\"BCI\") is the manager of Bain Capital XIV General Partner, LLC (\"BCPE Fund XIV GP\"), which is the general partner of Bain Capital Fund XIV, L.P. (\"BCPE Fund XIV\"), which is the managing member of BCPE Perseus Investor GP, LLC (\"BCPE Perseus GP\"), which is the general partner of BCPE Perseus. As a result, each of BCI, BCPE Fund XIV GP, BCPE Fund XIV and BCPE Perseus GP may be deemed to share voting and dispositive power with respect to the securities held by BCPE Perseus. BCI, BCPE Fund XIV GP, BCPE Fund XIV and BCPE Perseus GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."}],"balance_after":17857143,"source":{"system":"sec-edgar","filing":"0001193125-26-164417","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1040508/000119312526164417/ownership.xml","form_type":"4"}},{"id":804304,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-20T22:08:42.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":38300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to Dr. Koppel's continued service through each such vesting date."}],"balance_after":38300,"derivative":{"exercise_price":16,"expiration_date":"2036-04-16","underlying":"Common Stock","underlying_shares":38300},"source":{"system":"sec-edgar","filing":"0001193125-26-164407","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1578965/000119312526164407/ownership.xml","form_type":"4"}},{"id":804303,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-04-20T22:08:42.000Z","date":"2026-04-20","kind":"exercise","planned":false,"acquired":false,"shares":4145768,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents securities held directly by BCLS Fund IV Investments, LP (\"BCLS Fund IV Investments\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Dr. Koppel is a Partner of Bain Capital Life Sciences Investors, LLC (\"BCLSI\"). BCLSI is the ultimate general partner of BCLS Fund IV Investments. As a result, Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund IV Investments. Dr. Koppel disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4145768},"source":{"system":"sec-edgar","filing":"0001193125-26-164407","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1578965/000119312526164407/ownership.xml","form_type":"4"}},{"id":804302,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Preferred Stock","published_at":"2026-04-20T22:08:42.000Z","date":"2026-04-20","kind":"exercise","planned":false,"acquired":false,"shares":16875000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's Series A-1 Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's Series A-1 Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's Series A-1 Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents securities held directly by BCLS Fund IV Investments, LP (\"BCLS Fund IV Investments\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Dr. Koppel is a Partner of Bain Capital Life Sciences Investors, LLC (\"BCLSI\"). BCLSI is the ultimate general partner of BCLS Fund IV Investments. As a result, Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund IV Investments. Dr. Koppel disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":16875000},"source":{"system":"sec-edgar","filing":"0001193125-26-164407","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1578965/000119312526164407/ownership.xml","form_type":"4"}},{"id":804301,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-20T22:08:42.000Z","date":"2026-04-20","kind":"purchase","planned":false,"acquired":true,"shares":1562500,"price":16,"value":25000000.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents securities held directly by BCLS Fund IV Investments, LP (\"BCLS Fund IV Investments\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Dr. Koppel is a Partner of Bain Capital Life Sciences Investors, LLC (\"BCLSI\"). BCLSI is the ultimate general partner of BCLS Fund IV Investments. As a result, Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund IV Investments. Dr. Koppel disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":22583268,"source":{"system":"sec-edgar","filing":"0001193125-26-164407","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1578965/000119312526164407/ownership.xml","form_type":"4"}},{"id":804300,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-20T22:08:42.000Z","date":"2026-04-20","kind":"exercise","planned":false,"acquired":true,"shares":4145768,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents securities held directly by BCLS Fund IV Investments, LP (\"BCLS Fund IV Investments\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Dr. Koppel is a Partner of Bain Capital Life Sciences Investors, LLC (\"BCLSI\"). BCLSI is the ultimate general partner of BCLS Fund IV Investments. As a result, Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund IV Investments. Dr. Koppel disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":21020768,"source":{"system":"sec-edgar","filing":"0001193125-26-164407","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1578965/000119312526164407/ownership.xml","form_type":"4"}},{"id":804299,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":51911,"kind":"person","name":"Koppel Adam","position":1,"cik":"0001578965","reported_name":"Koppel Adam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-20T22:08:42.000Z","date":"2026-04-20","kind":"exercise","planned":false,"acquired":true,"shares":16875000,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's Series A-1 Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Represents securities held directly by BCLS Fund IV Investments, LP (\"BCLS Fund IV Investments\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Dr. Koppel is a Partner of Bain Capital Life Sciences Investors, LLC (\"BCLSI\"). BCLSI is the ultimate general partner of BCLS Fund IV Investments. As a result, Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund IV Investments. Dr. Koppel disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":16875000,"source":{"system":"sec-edgar","filing":"0001193125-26-164407","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1578965/000119312526164407/ownership.xml","form_type":"4"}},{"id":804274,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51905,"kind":"organization","name":"Bain Capital Life Sciences IV General Partner, LLC","position":2,"cik":"0001996931","reported_name":"Bain Capital Life Sciences IV General Partner, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51906,"kind":"organization","name":"Bain Capital Life Sciences Fund IV, L.P.","position":3,"cik":"0001996979","reported_name":"Bain Capital Life Sciences Fund IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51907,"kind":"organization","name":"BCLS Fund IV Investments GP, LLC","position":4,"cik":"0002015967","reported_name":"BCLS Fund IV Investments GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51908,"kind":"organization","name":"BCLS Fund IV Investments, L.P.","position":5,"cik":"0002015454","reported_name":"BCLS Fund IV Investments, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-04-20T22:01:46.000Z","date":"2026-04-20","kind":"exercise","planned":false,"acquired":false,"shares":4145768,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents securities held directly by BCLS Fund IV Investments, LP (\"BCLS Fund IV Investments\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bain Capital Life Sciences Investors, LLC (\"BCLSI\") is the manager of Bain Capital Life Sciences IV General Partner, LLC (\"BCLS Fund IV GP\"), which is the general partner of Bain Capital Life Sciences Fund IV, L.P. (\"BCLS Fund IV\"), which is the managing member of BCLS Fund IV Investments GP, LLC (\"BCLS Fund IV Investments GP\"), which is the general partner of BCLS Fund IV Investments. As a result, each of BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Fund IV Investments GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund IV Investments. BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Fund IV Investments GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4145768},"source":{"system":"sec-edgar","filing":"0001193125-26-164389","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1703031/000119312526164389/ownership.xml","form_type":"4"}},{"id":804273,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51905,"kind":"organization","name":"Bain Capital Life Sciences IV General Partner, LLC","position":2,"cik":"0001996931","reported_name":"Bain Capital Life Sciences IV General Partner, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51906,"kind":"organization","name":"Bain Capital Life Sciences Fund IV, L.P.","position":3,"cik":"0001996979","reported_name":"Bain Capital Life Sciences Fund IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51907,"kind":"organization","name":"BCLS Fund IV Investments GP, LLC","position":4,"cik":"0002015967","reported_name":"BCLS Fund IV Investments GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51908,"kind":"organization","name":"BCLS Fund IV Investments, L.P.","position":5,"cik":"0002015454","reported_name":"BCLS Fund IV Investments, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Preferred Stock","published_at":"2026-04-20T22:01:46.000Z","date":"2026-04-20","kind":"exercise","planned":false,"acquired":false,"shares":16875000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's Series A-1 Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's Series A-1 Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's Series A-1 Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents securities held directly by BCLS Fund IV Investments, LP (\"BCLS Fund IV Investments\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bain Capital Life Sciences Investors, LLC (\"BCLSI\") is the manager of Bain Capital Life Sciences IV General Partner, LLC (\"BCLS Fund IV GP\"), which is the general partner of Bain Capital Life Sciences Fund IV, L.P. (\"BCLS Fund IV\"), which is the managing member of BCLS Fund IV Investments GP, LLC (\"BCLS Fund IV Investments GP\"), which is the general partner of BCLS Fund IV Investments. As a result, each of BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Fund IV Investments GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund IV Investments. BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Fund IV Investments GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":16875000},"source":{"system":"sec-edgar","filing":"0001193125-26-164389","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1703031/000119312526164389/ownership.xml","form_type":"4"}},{"id":804272,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51905,"kind":"organization","name":"Bain Capital Life Sciences IV General Partner, LLC","position":2,"cik":"0001996931","reported_name":"Bain Capital Life Sciences IV General Partner, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51906,"kind":"organization","name":"Bain Capital Life Sciences Fund IV, L.P.","position":3,"cik":"0001996979","reported_name":"Bain Capital Life Sciences Fund IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51907,"kind":"organization","name":"BCLS Fund IV Investments GP, LLC","position":4,"cik":"0002015967","reported_name":"BCLS Fund IV Investments GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51908,"kind":"organization","name":"BCLS Fund IV Investments, L.P.","position":5,"cik":"0002015454","reported_name":"BCLS Fund IV Investments, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-20T22:01:46.000Z","date":"2026-04-20","kind":"purchase","planned":false,"acquired":true,"shares":1562500,"price":16,"value":25000000.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents securities held directly by BCLS Fund IV Investments, LP (\"BCLS Fund IV Investments\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bain Capital Life Sciences Investors, LLC (\"BCLSI\") is the manager of Bain Capital Life Sciences IV General Partner, LLC (\"BCLS Fund IV GP\"), which is the general partner of Bain Capital Life Sciences Fund IV, L.P. (\"BCLS Fund IV\"), which is the managing member of BCLS Fund IV Investments GP, LLC (\"BCLS Fund IV Investments GP\"), which is the general partner of BCLS Fund IV Investments. As a result, each of BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Fund IV Investments GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund IV Investments. BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Fund IV Investments GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."}],"balance_after":22583268,"source":{"system":"sec-edgar","filing":"0001193125-26-164389","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1703031/000119312526164389/ownership.xml","form_type":"4"}},{"id":804271,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51905,"kind":"organization","name":"Bain Capital Life Sciences IV General Partner, LLC","position":2,"cik":"0001996931","reported_name":"Bain Capital Life Sciences IV General Partner, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51906,"kind":"organization","name":"Bain Capital Life Sciences Fund IV, L.P.","position":3,"cik":"0001996979","reported_name":"Bain Capital Life Sciences Fund IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51907,"kind":"organization","name":"BCLS Fund IV Investments GP, LLC","position":4,"cik":"0002015967","reported_name":"BCLS Fund IV Investments GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51908,"kind":"organization","name":"BCLS Fund IV Investments, L.P.","position":5,"cik":"0002015454","reported_name":"BCLS Fund IV Investments, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-20T22:01:46.000Z","date":"2026-04-20","kind":"exercise","planned":false,"acquired":true,"shares":4145768,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents securities held directly by BCLS Fund IV Investments, LP (\"BCLS Fund IV Investments\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bain Capital Life Sciences Investors, LLC (\"BCLSI\") is the manager of Bain Capital Life Sciences IV General Partner, LLC (\"BCLS Fund IV GP\"), which is the general partner of Bain Capital Life Sciences Fund IV, L.P. (\"BCLS Fund IV\"), which is the managing member of BCLS Fund IV Investments GP, LLC (\"BCLS Fund IV Investments GP\"), which is the general partner of BCLS Fund IV Investments. As a result, each of BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Fund IV Investments GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund IV Investments. BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Fund IV Investments GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."}],"balance_after":21020768,"source":{"system":"sec-edgar","filing":"0001193125-26-164389","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1703031/000119312526164389/ownership.xml","form_type":"4"}},{"id":804270,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":44733,"kind":"organization","name":"Bain Capital Life Sciences Investors, LLC","position":1,"cik":"0001703031","reported_name":"Bain Capital Life Sciences Investors, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51905,"kind":"organization","name":"Bain Capital Life Sciences IV General Partner, LLC","position":2,"cik":"0001996931","reported_name":"Bain Capital Life Sciences IV General Partner, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51906,"kind":"organization","name":"Bain Capital Life Sciences Fund IV, L.P.","position":3,"cik":"0001996979","reported_name":"Bain Capital Life Sciences Fund IV, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51907,"kind":"organization","name":"BCLS Fund IV Investments GP, LLC","position":4,"cik":"0002015967","reported_name":"BCLS Fund IV Investments GP, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51908,"kind":"organization","name":"BCLS Fund IV Investments, L.P.","position":5,"cik":"0002015454","reported_name":"BCLS Fund IV Investments, L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-20T22:01:46.000Z","date":"2026-04-20","kind":"exercise","planned":false,"acquired":true,"shares":16875000,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's Series A-1 Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents securities held directly by BCLS Fund IV Investments, LP (\"BCLS Fund IV Investments\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Bain Capital Life Sciences Investors, LLC (\"BCLSI\") is the manager of Bain Capital Life Sciences IV General Partner, LLC (\"BCLS Fund IV GP\"), which is the general partner of Bain Capital Life Sciences Fund IV, L.P. (\"BCLS Fund IV\"), which is the managing member of BCLS Fund IV Investments GP, LLC (\"BCLS Fund IV Investments GP\"), which is the general partner of BCLS Fund IV Investments. As a result, each of BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Fund IV Investments GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund IV Investments. BCLSI, BCLS Fund IV GP, BCLS Fund IV and BCLS Fund IV Investments GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein."}],"balance_after":16875000,"source":{"system":"sec-edgar","filing":"0001193125-26-164389","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1703031/000119312526164389/ownership.xml","form_type":"4"}},{"id":804520,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":51946,"kind":"person","name":"Kaplan Andrew T.","position":1,"cik":"0001752059","reported_name":"Kaplan Andrew T.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-20T22:00:25.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":38300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to Mr. Kaplan's continued service through each such vesting date."}],"balance_after":38300,"derivative":{"exercise_price":16,"expiration_date":"2036-04-16","underlying":"Common Stock","underlying_shares":38300},"source":{"system":"sec-edgar","filing":"0001193125-26-164388","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1752059/000119312526164388/ownership.xml","form_type":"4"}},{"id":804519,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":51946,"kind":"person","name":"Kaplan Andrew T.","position":1,"cik":"0001752059","reported_name":"Kaplan Andrew T.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-04-20T22:00:25.000Z","date":"2026-04-20","kind":"exercise","planned":false,"acquired":false,"shares":17857143,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents securities held directly by BCPE Perseus Investor, LP (\"BCPE Perseus\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Mr. Kaplan is a Partner of Bain Capital Investors, LLC (\"BCI\"). BCI is the ultimate general partner of BCPE Perseus. As a result, Mr. Kaplan may be deemed to share voting and dispositive power with respect to the securities held by BCPE Perseus. Mr. Kaplan disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":17857143},"source":{"system":"sec-edgar","filing":"0001193125-26-164388","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1752059/000119312526164388/ownership.xml","form_type":"4"}},{"id":804518,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":51946,"kind":"person","name":"Kaplan Andrew T.","position":1,"cik":"0001752059","reported_name":"Kaplan Andrew T.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-20T22:00:25.000Z","date":"2026-04-20","kind":"purchase","planned":false,"acquired":true,"shares":8398438,"price":16,"value":134375008.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents securities held directly by BCPE Perseus Investor, LP (\"BCPE Perseus\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Mr. Kaplan is a Partner of Bain Capital Investors, LLC (\"BCI\"). BCI is the ultimate general partner of BCPE Perseus. As a result, Mr. Kaplan may be deemed to share voting and dispositive power with respect to the securities held by BCPE Perseus. Mr. Kaplan disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":26255581,"source":{"system":"sec-edgar","filing":"0001193125-26-164388","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1752059/000119312526164388/ownership.xml","form_type":"4"}},{"id":804517,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":51946,"kind":"person","name":"Kaplan Andrew T.","position":1,"cik":"0001752059","reported_name":"Kaplan Andrew T.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-04-20T22:00:25.000Z","date":"2026-04-20","kind":"exercise","planned":false,"acquired":true,"shares":17857143,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents securities held directly by BCPE Perseus Investor, LP (\"BCPE Perseus\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Mr. Kaplan is a Partner of Bain Capital Investors, LLC (\"BCI\"). BCI is the ultimate general partner of BCPE Perseus. As a result, Mr. Kaplan may be deemed to share voting and dispositive power with respect to the securities held by BCPE Perseus. Mr. Kaplan disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein."}],"balance_after":17857143,"source":{"system":"sec-edgar","filing":"0001193125-26-164388","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1752059/000119312526164388/ownership.xml","form_type":"4"}},{"id":804266,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":51901,"kind":"person","name":"Cloghessy Paula","position":1,"cik":"0001744682","reported_name":"Cloghessy Paula","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-04-20T21:19:23.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest and become exercisable, if at all,  as to all of the underlying shares if (i) the average daily closing price of the Company's common stock on Nasdaq during any 30 consecutive calendar-day period during the period beginning October 16, 2026 and ending on April 16, 2030 (the \"Performance Measurement Period\"), or (ii) the stock price in a change in control transaction that occurs during the Performance Measurement Period, equals or exceeds $40 per share, in each case subject to the Reporting Person's continued service through such vesting date."}],"balance_after":60000,"derivative":{"exercise_price":16,"expiration_date":"2036-04-16","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001193125-26-164307","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744682/000119312526164307/ownership.xml","form_type":"4"}},{"id":804265,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":51901,"kind":"person","name":"Cloghessy Paula","position":1,"cik":"0001744682","reported_name":"Cloghessy Paula","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief People Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-04-20T21:19:23.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest and become exercisable as to 25% of the underlying shares on April 16, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service through each such vesting date."}],"balance_after":60000,"derivative":{"exercise_price":16,"expiration_date":"2036-04-16","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001193125-26-164307","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744682/000119312526164307/ownership.xml","form_type":"4"}},{"id":804527,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":51948,"kind":"person","name":"Akamine Scott","position":1,"cik":"0001816720","reported_name":"Akamine Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-04-20T21:19:15.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest and become exercisable, if at all,  as to all of the underlying shares if (i) the average daily closing price of the Company's common stock on Nasdaq during any 30 consecutive calendar-day period during the period beginning October 16, 2026 and ending on April 16, 2030 (the \"Performance Measurement Period\"), or (ii) the stock price in a change in control transaction that occurs during the Performance Measurement Period, equals or exceeds $40 per share, in each case subject to the Reporting Person's continued service through such vesting date."}],"balance_after":60000,"derivative":{"exercise_price":16,"expiration_date":"2036-04-16","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001193125-26-164306","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1816720/000119312526164306/ownership.xml","form_type":"4"}},{"id":804526,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":51948,"kind":"person","name":"Akamine Scott","position":1,"cik":"0001816720","reported_name":"Akamine Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-04-20T21:19:15.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest and become exercisable as to 25% of the underlying shares on April 16, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service through each such vesting date."}],"balance_after":60000,"derivative":{"exercise_price":16,"expiration_date":"2036-04-16","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001193125-26-164306","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816720/000119312526164306/ownership.xml","form_type":"4"}},{"id":804349,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Stock Option (right to buy)","published_at":"2026-04-20T21:18:00.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest and become exercisable, if at all,  as to all of the underlying shares if (i) the average daily closing price of the Company's common stock on Nasdaq during any 30 consecutive calendar-day period during the period beginning October 16, 2026 and ending on April 16, 2030 (the \"Performance Measurement Period\"), or (ii) the stock price in a change in control transaction that occurs during the Performance Measurement Period, equals or exceeds $40 per share, in each case subject to the Reporting Person's continued service through such vesting date."}],"balance_after":300000,"derivative":{"exercise_price":16,"expiration_date":"2036-04-16","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001193125-26-164299","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1354434/000119312526164299/ownership.xml","form_type":"4"}},{"id":804348,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":39179,"kind":"person","name":"Renaud Ronald C JR","position":1,"cik":"0001354434","reported_name":"Renaud Ronald C JR","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Stock Option (right to buy)","published_at":"2026-04-20T21:18:00.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest and become exercisable as to 25% of the underlying shares on April 16, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service through each such vesting date."}],"balance_after":300000,"derivative":{"exercise_price":16,"expiration_date":"2036-04-16","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001193125-26-164299","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1354434/000119312526164299/ownership.xml","form_type":"4"}},{"id":804269,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":51903,"kind":"person","name":"Burgess Paul D.","position":1,"cik":"0001744627","reported_name":"Burgess Paul D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2026-04-20T21:14:12.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest and become exercisable, if at all,  as to all of the underlying shares if (i) the average daily closing price of the Company's common stock on Nasdaq during any 30 consecutive calendar-day period during the period beginning October 16, 2026 and ending on April 16, 2030 (the \"Performance Measurement Period\"), or (ii) the stock price in a change in control transaction that occurs during the Performance Measurement Period, equals or exceeds $40 per share, in each case subject to the Reporting Person's continued service through such vesting date."}],"balance_after":100000,"derivative":{"exercise_price":16,"expiration_date":"2036-04-16","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001193125-26-164275","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744627/000119312526164275/ownership.xml","form_type":"4"}},{"id":804268,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":51903,"kind":"person","name":"Burgess Paul D.","position":1,"cik":"0001744627","reported_name":"Burgess Paul D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2026-04-20T21:14:12.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest and become exercisable as to 25% of the underlying shares on April 16, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service through each such vesting date."}],"balance_after":100000,"derivative":{"exercise_price":16,"expiration_date":"2036-04-16","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001193125-26-164275","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744627/000119312526164275/ownership.xml","form_type":"4"}},{"id":804370,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":16046,"kind":"person","name":"MILLIGAN JOHN F","position":1,"cik":"0001191589","reported_name":"MILLIGAN JOHN F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-20T21:13:40.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":38300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to the Reporting Person's continued service through each such vesting date."}],"balance_after":38300,"derivative":{"exercise_price":16,"expiration_date":"2036-04-16","underlying":"Common Stock","underlying_shares":38300},"source":{"system":"sec-edgar","filing":"0001193125-26-164271","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1191589/000119312526164271/ownership.xml","form_type":"4"}},{"id":804156,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":51875,"kind":"person","name":"Coleman Jamie Beth","position":1,"cik":"0002118765","reported_name":"Coleman Jamie Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-04-20T21:13:05.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest and become exercisable, if at all,  as to all of the underlying shares if (i) the average daily closing price of the Company's common stock on Nasdaq during any 30 consecutive calendar-day period during the period beginning October 16, 2026 and ending on April 16, 2030 (the \"Performance Measurement Period\"), or (ii) the stock price in a change in control transaction that occurs during the Performance Measurement Period, equals or exceeds $40 per share, in each case subject to the Reporting Person's continued service through such vesting date."}],"balance_after":75000,"derivative":{"exercise_price":16,"expiration_date":"2036-04-16","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001193125-26-164264","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2096997/000119312526164264/ownership.xml","form_type":"4"}},{"id":804155,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":51875,"kind":"person","name":"Coleman Jamie Beth","position":1,"cik":"0002118765","reported_name":"Coleman Jamie Beth","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-04-20T21:13:05.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest and become exercisable as to 25% of the underlying shares on April 16, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service through each such vesting date."}],"balance_after":75000,"derivative":{"exercise_price":16,"expiration_date":"2036-04-16","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001193125-26-164264","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2096997/000119312526164264/ownership.xml","form_type":"4"}},{"id":804398,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":16976,"kind":"person","name":"MACKAY MARTIN","position":1,"cik":"0001414815","reported_name":"MACKAY MARTIN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-20T21:10:09.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":38300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to the Reporting Person's continued service through each such vesting date."}],"balance_after":38300,"derivative":{"exercise_price":16,"expiration_date":"2036-04-16","underlying":"Common Stock","underlying_shares":38300},"source":{"system":"sec-edgar","filing":"0001193125-26-164253","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1414815/000119312526164253/ownership.xml","form_type":"4"}},{"id":804154,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":51874,"kind":"person","name":"Wasserman Scott M.","position":1,"cik":"0002118767","reported_name":"Wasserman Scott M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-04-20T21:08:56.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest and become exercisable, if at all,  as to all of the underlying shares if (i) the average daily closing price of the Company's common stock on Nasdaq during any 30 consecutive calendar-day period during the period beginning October 16, 2026 and ending on April 16, 2030 (the \"Performance Measurement Period\"), or (ii) the stock price in a change in control transaction that occurs during the Performance Measurement Period, equals or exceeds $40 per share, in each case subject to the Reporting Person's continued service through such vesting date."}],"balance_after":100000,"derivative":{"exercise_price":16,"expiration_date":"2036-04-16","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001193125-26-164243","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2096997/000119312526164243/ownership.xml","form_type":"4"}},{"id":804153,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":51874,"kind":"person","name":"Wasserman Scott M.","position":1,"cik":"0002118767","reported_name":"Wasserman Scott M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-04-20T21:08:56.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest and become exercisable as to 25% of the underlying shares on April 16, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service through each such vesting date."}],"balance_after":100000,"derivative":{"exercise_price":16,"expiration_date":"2036-04-16","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001193125-26-164243","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2096997/000119312526164243/ownership.xml","form_type":"4"}},{"id":804525,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":21665,"kind":"person","name":"Hite Christopher","position":1,"cik":"0001814238","reported_name":"Hite Christopher","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-20T21:05:01.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":38300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to the Reporting Person's continued service through each such vesting date."}],"balance_after":38300,"derivative":{"exercise_price":16,"expiration_date":"2036-04-16","underlying":"Common Stock","underlying_shares":38300},"source":{"system":"sec-edgar","filing":"0001193125-26-164226","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1814238/000119312526164226/ownership.xml","form_type":"4"}},{"id":804264,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":11689,"kind":"person","name":"Clyburn Frank","position":1,"cik":"0001763963","reported_name":"Clyburn Frank","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-20T21:04:32.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":38300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest and become exercisable as to 100% of the underlying shares on April 16, 2027, subject to the Reporting Person's continued service through each such vesting date."}],"balance_after":38300,"derivative":{"exercise_price":16,"expiration_date":"2036-04-16","underlying":"Common Stock","underlying_shares":38300},"source":{"system":"sec-edgar","filing":"0001193125-26-164224","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1763963/000119312526164224/ownership.xml","form_type":"4"}},{"id":804286,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":51909,"kind":"person","name":"Pagan Douglas W.","position":1,"cik":"0001628880","reported_name":"Pagan Douglas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-04-20T21:01:51.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest and become exercisable, if at all,  as to all of the underlying shares if (i) the average daily closing price of the Company's common stock on Nasdaq during any 30 consecutive calendar-day period during the period beginning October 16, 2026 and ending on April 16, 2030 (the \"Performance Measurement Period\"), or (ii) the stock price in a change in control transaction that occurs during the Performance Measurement Period, equals or exceeds $40 per share, in each case subject to the Reporting Person's continued service through such vesting date."}],"balance_after":100000,"derivative":{"exercise_price":16,"expiration_date":"2036-04-16","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001193125-26-164210","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1628880/000119312526164210/ownership.xml","form_type":"4"}},{"id":804285,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":51909,"kind":"person","name":"Pagan Douglas W.","position":1,"cik":"0001628880","reported_name":"Pagan Douglas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-04-20T21:01:51.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest and become exercisable as to 25% of the underlying shares on April 16, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service through each such vesting date."}],"balance_after":100000,"derivative":{"exercise_price":16,"expiration_date":"2036-04-16","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001193125-26-164210","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628880/000119312526164210/ownership.xml","form_type":"4"}}]}